Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases

References

• Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009;7:328–31
   PubMed Web of Science ®Google Scholar
• Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 2015;64:830–41
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115–26
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010;56:1–7
   PubMed Web of Science ®Google Scholar
• Piazza G, Goldhaber SZ. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 2010;121:2146–50
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835–46
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773–9
   PubMed Web of Science ®Google Scholar
• Lind C, Flinterman LE, Enga KF, et al. Impact of incident venous thromboembolism on risk of arterial thrombotic diseases. Circulation 2014;129:855–63
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Horvath-Puho E, Søgaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009;7:521–8
   PubMed Web of Science ®Google Scholar
• Tao H, Yang JJ, Shi KH, et al. The significance of YKL-40 protein in liver fibrosis. Inflamm Res 2014;63:249–54
   PubMed Web of Science ®Google Scholar
• Heymann F, Tacke F. Immunology in the liver - from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016;13:88–110
   PubMed Web of Science ®Google Scholar
• Seo W, Jeong WI. Hepatic non-parenchymal cells: master regulators of alcoholic liver disease? World J Gastroenterol 2016;22:1348–56
   PubMed Web of Science ®Google Scholar
• Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221–5
   PubMed Web of Science ®Google Scholar
• Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504–9
   PubMedGoogle Scholar
• Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999;19:687–94
   PubMed Web of Science ®Google Scholar
• Millis AJ, Hoyle M, Kent L. In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 1986;127:366–72
   PubMed Web of Science ®Google Scholar
• Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270:13076–83
   PubMed Web of Science ®Google Scholar
• Malinda KM, Ponce L, Kleinman HK, et al. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168–73
   PubMed Web of Science ®Google Scholar
• Nishikawa KC, Millis AJT. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79–87
   PubMed Web of Science ®Google Scholar
• Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011;73:479–501
   PubMed Web of Science ®Google Scholar
• Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122
   PubMed Web of Science ®Google Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172–209
   PubMed Web of Science ®Google Scholar
• Johansen JS, Møller S, Price PA, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582–90
   PubMed Web of Science ®Google Scholar
• Johansen JS, Christoffersen P, Møller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911–20
   PubMed Web of Science ®Google Scholar
• Nøjgaard C, Johansen JS, Christensen E, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179–86
   PubMed Web of Science ®Google Scholar
• Nøjgaard C, Høst NB, Christensen IJ, et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257–63
   PubMed Web of Science ®Google Scholar
• Wang Y, Ripa RS, Johansen JS, et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 2008;42:295–302
   PubMed Web of Science ®Google Scholar
• Hedegaard A, Ripa RS, Johansen JS, et al. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010;70:80–6
   PubMed Web of Science ®Google Scholar
• Park HY, Jun CD, Jeon SJ, et al. Serum YKL-40 levels correlate with infarct volume, stroke severity, and functional outcome in acute ischemic stroke patients. PLoS One 2012;7:e51722
   PubMed Web of Science ®Google Scholar
• Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population. Stroke 2015;46:329–35
   PubMed Web of Science ®Google Scholar
• Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Observationally and genetically high YKL-40 and risk of venous thromboembolism in the general population: cohort and Mendelian randomization studies. Arterioscler Thromb Vasc Biol 2016;36:1030–6
   PubMed Web of Science ®Google Scholar
• Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS. YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: cohort and Mendelian randomization studies. Clin Chem 2014;60:1429–40
   PubMed Web of Science ®Google Scholar
• Tran A, Benzaken S, Saint-Paul MC, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000;12:989–93
   PubMed Web of Science ®Google Scholar
• Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501–12
   PubMed Web of Science ®Google Scholar
• Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803–10
   PubMed Web of Science ®Google Scholar
• Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417–26
   PubMed Web of Science ®Google Scholar
• Harvey S, Weisman M, O'Dell J, et al. Chondrex: new marker of joint disease. Clin Chem 1998;44:509–16
   PubMed Web of Science ®Google Scholar
• Mohanty AK, Singh G, Paramasivam M, et al. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. J Biol Chem 2003;278:14451–60
   PubMed Web of Science ®Google Scholar
• De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926–31
   PubMed Web of Science ®Google Scholar
• Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002;365:119–26
   PubMed Web of Science ®Google Scholar
• Faibish M, Francescone R, Bentley B, et al. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011;10:742–51
   PubMed Web of Science ®Google Scholar
• Kim MN, Lee KE, Hong JY, et al. Involvement of the MAPK and PI3K pathways in chitinase 3-like 1-regulated hyperoxia-induced airway epithelial cell death. Biochem Biophys Res Commun 2012;421:790–6
   PubMed Web of Science ®Google Scholar
• Fusetti F, Pijning T, Kalk KH, et al. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem 2003;278:37753–60
   PubMed Web of Science ®Google Scholar
• Chang NC, Hung SI, Hwa KY, et al. A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem 2001;276:17497–506
   PubMed Web of Science ®Google Scholar
• Shao R, Hamel K, Petersen L, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456–68
   PubMed Web of Science ®Google Scholar
• Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 2011;286:15332–43
   PubMed Web of Science ®Google Scholar
• Clarke DN, Al Ahmad A, Lee B, et al. Perlecan domain V induces VEGf secretion in brain endothelial cells through integrin α5β1 and ERK-dependent signaling pathways. PLoS One 2012;7:e45257
   PubMed Web of Science ®Google Scholar
• Lee B, Clarke D, Al Ahmad A, et al. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents. J Clin Invest 2011;121:3005–23
   PubMed Web of Science ®Google Scholar
• He CH, Lee CG, Dela Cruz CS, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep 2013;4:830–41
   PubMed Web of Science ®Google Scholar
• Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39–48
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805–12
   PubMed Web of Science ®Google Scholar
• Nordenbaek C, Johansen JS, Junker P, et al. YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. J Infect Dis 1999;180:1722–6
   PubMed Web of Science ®Google Scholar
• Kornblit B, Hellemann D, Munthe-Fog L, et al. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology 2013;218:1227–34
   PubMed Web of Science ®Google Scholar
• Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004;380:651–9
   PubMed Web of Science ®Google Scholar
• Johansen JS, Høyer PE, Larsen LA, et al. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007;55:1213–28
   PubMed Web of Science ®Google Scholar
• Kawamura K, Shibata T, Saget O, et al. A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells. Development 1999;126:211–19
   PubMed Web of Science ®Google Scholar
• Badariotti F, Kypriotou M, Lelong C, et al. The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HC-gp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes. J Biol Chem 2006;281:29583–96
   PubMed Web of Science ®Google Scholar
• Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206:1149–66
   PubMed Web of Science ®Google Scholar
• Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949–55
   PubMedGoogle Scholar
• Kjaergaard AD, Bojesen SE, Johansen JS, Nordestgaard BG. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010;68:672–80
   PubMed Web of Science ®Google Scholar
• Kjaergaard AD, Johansen JS, Nordestgaard BG, Bojesen SE. Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. J Med Genet 2013;50:831–7
   PubMed Web of Science ®Google Scholar
• Johansen JS, Lottenburger T, Nielsen HJ, et al. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2603–8
   PubMed Web of Science ®Google Scholar
• Vuolteenaho K, Leppänen T, Kekkonen R, et al. Running a marathon induces changes in adipokine levels and in markers of cartilage degradation-novel role for resistin. PLoS One 2014;9:e110481
   PubMed Web of Science ®Google Scholar
• Johansen JS, Bojesen SE, Tybjaerg-Hansen A, et al. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 2010;56:1580–91
   PubMed Web of Science ®Google Scholar
• Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 2011;412:709–12
   PubMed Web of Science ®Google Scholar
• Kastrup J, Johansen JS, Winkel P, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009;30:1066–72
   PubMed Web of Science ®Google Scholar
• Rathcke CN, Thomsen SB, Linneberg A, Vestergaard H. Variations of CHI3L1, levels of the encoded glycoprotein YKL-40 and prediction of fatal and non-fatal ischemic stroke. PLoS One 2012;7:e43498
   PubMed Web of Science ®Google Scholar
• Ridker PM, Chasman DI, Rose L, et al. Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events. J Am Heart Assoc 2014;3:e000897
   Web of Science ®Google Scholar
• Bonneh-Barkay D, Wang G, Starkey A, et al. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation 2010;7:34
   PubMed Web of Science ®Google Scholar
• Longstreth W, Jr. Brain vascular disease overt and covert. Stroke 2005;36:2062–3
   PubMed Web of Science ®Google Scholar
• Kucur M, Isman FK, Karadag B, et al. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007;18:391–6
   PubMed Web of Science ®Google Scholar
• Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol 2010;9:86
   PubMed Web of Science ®Google Scholar
• Mathiasen AB, Harutyunyan MJ, Jørgensen E, et al. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest 2011;71:439–47
   PubMed Web of Science ®Google Scholar
• Kim HM, Lee BW, Song YM, et al. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2012;11:84
   PubMed Web of Science ®Google Scholar
• Xie F, Qian Q, Chen Z, et al. Chitinase 3-like 1 gene-329G/A polymorphism, plasma concentration and risk of coronary heart disease in a Chinese population.l. Gene 2012;499:135–8
   PubMed Web of Science ®Google Scholar
• Rehli M, Niller HH, Ammon C, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003;278:44058–67
   PubMed Web of Science ®Google Scholar
• Zhao X, Tang R, Gao B, et al. Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007;80:12–8
   PubMed Web of Science ®Google Scholar
• Singh SK, Bhardwaj R, Wilczynska KM, et al. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem 2011;286:39893–903
   PubMed Web of Science ®Google Scholar
• Kruit A, Grutters JC, Ruven HJT, et al. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 2007;101:1563–71
   PubMed Web of Science ®Google Scholar
• Ober C, Tan Z, Sun Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008;358:1682–91
   PubMed Web of Science ®Google Scholar
• Yang MS, Morris DW, Donohoe G, et al. Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a potential functional mechanism. Biol Psychiatry 2008;64:98–103
   PubMed Web of Science ®Google Scholar
• Berres ML, Papen S, Pauels K, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009;50:370–6
   PubMed Web of Science ®Google Scholar
• Sohn MH, Lee JH, Kim KW, et al. Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009;179:449–56
   PubMed Web of Science ®Google Scholar
• Nielsen KR, Steffensen R, Boegsted M, et al. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther 2011;13:R109
   PubMed Web of Science ®Google Scholar
• Zheng JL, Lu L, Hu J, et al. Genetic polymorphisms in chitinase 3-like 1 (CHI3L1) are associated with circulating YKL-40 levels, but not with angiographic coronary artery disease in a Chinese population. Cytokine 2011;54:51–5
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Litman HJ, Dienstag JL, et al. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int 2012;32:665–74
   PubMed Web of Science ®Google Scholar
• Yamamori H, Hashimoto R, Ohi K, et al. A promoter variant in the chitinase 3-like 1 gene is associated with serum YKL-40 level and personality trait. Neurosci Lett 2012;513:204–8
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Harbord RM, Sterne JAC, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133–63
   PubMed Web of Science ®Google Scholar
• Eurich D, Neumann UP, Boas-Knoop S, et al. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease. J Gastroenterol Hepatol 2013;28:153–60
   PubMed Web of Science ®Google Scholar
• Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95
   PubMed Web of Science ®Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335–62
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949–52
   PubMed Web of Science ®Google Scholar
• Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476–81
   PubMed Web of Science ®Google Scholar
• Esmat G, Metwally M, Zalata KR, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007;46:620–7
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Goodman ZD, Dienstag JL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–98
   PubMed Web of Science ®Google Scholar
• Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008;103:928–36
   PubMed Web of Science ®Google Scholar
• Pungpapong S, Nunes DP, Krishna M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008;14:1294–302
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009;7:219–26
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Dienstag JL, Bonkovsky HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401–9
   PubMed Web of Science ®Google Scholar
• Rath T, Roderfeld M, Güler C, et al. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol 2011;46:1369–80
   PubMed Web of Science ®Google Scholar
• Mygind ND, Harutyunyan MJ, Mathiasen AB, et al. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011;60:281–7
   PubMed Web of Science ®Google Scholar
• Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449–57
   PubMed Web of Science ®Google Scholar
• Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009;49:1017–44
   PubMed Web of Science ®Google Scholar
• Junker N, Johansen JS, Hansen LT, et al. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005;96:183–90
   PubMed Web of Science ®Google Scholar